Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Schmidt-Erfurth U, et al. Among authors: gray t. Arch Ophthalmol. 1999 Sep;117(9):1177-87. doi: 10.1001/archopht.117.9.1177. Arch Ophthalmol. 1999. PMID: 10496389 Clinical Trial.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES. Miller JW, et al. Among authors: gray t. Arch Ophthalmol. 1999 Sep;117(9):1161-73. doi: 10.1001/archopht.117.9.1161. Arch Ophthalmol. 1999. PMID: 10496388 Clinical Trial.
A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Sickenberg M, et al. Among authors: gray t. Arch Ophthalmol. 2000 Mar;118(3):327-36. doi: 10.1001/archopht.118.3.327. Arch Ophthalmol. 2000. PMID: 10721954 Clinical Trial.
Improvement after verteporfin therapy.
Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L, Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M, Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy" Writting Committee for TAP Study Group. Anand R, et al. Arch Ophthalmol. 2003 Mar;121(3):415-6. doi: 10.1001/archopht.121.3.415. Arch Ophthalmol. 2003. PMID: 12617718 No abstract available.
Genomic investigation and clinical correlates of the in vitro β-lactam: NaHCO3 responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial.
Petersiel N, Giulieri S, Daniel DS, Fan S-H, Ersoy SC, Davis JS, Bayer AS, Howden BP, Tong SYC; CAMERA2 study group. Petersiel N, et al. Antimicrob Agents Chemother. 2024 Jun 5:e0021824. doi: 10.1128/aac.00218-24. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 38837393
1,161 results